General
Preferred name
RISEDRONIC ACID
Synonyms
RISEDRONATE SODIUM ()
Risedronic Acid Sodium ()
NE 58095 Sodium ()
risedronate ()
Risedronic acid monohydrate ()
Risedronic acid (Actonel) ()
Risedronate (sodium) ()
Risedronic acid (sodium) ()
NE-58095 ()
Risedronate monosodium ()
Actonel ()
NE-58095 ANHYDROUS ()
Atelvia ()
NSC-722598 ()
Risedronic acid monosodium salt ()
Risedronate sodium anhydrous ()
NSC-759280 ()
M05BA07 ()
Ridron ()
Risedronate ()
Acido risedronico ()
Acide risedronique ()
Risedronate (sodium salt) ()
P&D ID
PD009664
CAS
115436-72-1
105462-24-6
122458-82-6
Tags
available
drug
probe
Approved by
FDA
First approval
1998
Drug indication
Paget's disease
Regulator (calcium)
Drug Status
approved
investigational
Max Phase
4.0
Probe info
Probe selectivity
protein-selective
Probe type
calculated probe
Probe sources
Probe targets
[[ compound.targets[t].gene_name ]]
Probe control
Orthogonal probes
1
No orthogonal probes found
Similar probes
1
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS
Risedronate is a pyridine-based bisphosphonate that inhibits bone resorption caused by osteoclasts[FDA Label].
MOA
Risedronatic acid binds to bone hydroxyapatite[FDA Label]. Bone resorption causes local acidification, releasing risedronic acid which is that taken into osteoclasts by fluid-phase endocytosis[A959]. Endocytic vesicles are acidified, releasing risedronic acid to the cytosol of osteoclasts where they induce apoptosis through inhbition of farnesyl pyrophosphate synthase[A959]. Inhibition of osteoclasts results in decreased bone resorption[A959].
INDICATION
Risedronic acid is indicated for the treatment of osteoperosis in men, treatment of Paget's disease, treatment and prevention of osteoperosis in postmenopausal women, and treatment and prevention of glucocorticoid-induced osteoperosis[FDA Label].
ROE
Risedronate is excreted by the kidneys and the unabsorbed dose is eliminated in the feces[FDA Label].
TOXICITY
In clinical trials, over 10% of patients experienced back pain, arthralgia, abdominal pain, and dyspepsia[FDA Label]. Less commonly, patients experience angioedema, generalized rash, bullous skin reactions, iritis, and uveitis[FDA Label].; ; Patients experiencing an overdose may experience a decrease in serum calcium and phosphorus[FDA Label]. Patients can be given milk or antacids to bind the drug and reduce its absorption[FDA Label]. In more severe cases, patients may require gastric lavage and intravenous calcium[FDA Label]. A lethal dose in rats is equivalent to 320 to 620 times the human dose based on surface area[FDA Label].
METABOLISM
Risedronic acid is not likely not metabolized before elimination[FDA Label]. The P-C-P group of bisphosphonates is resistant to chemical and enzymatic hydrolysis preventing metabolism of the molecule[A959].
ABSORPTION
Oral bioavailability is 0.63% and maximum absorption is approximately 1 hour after dosing[FDA Label]. Administration half and hour before a meal reduces bioavailability by 55% compared to fasting and dosing 1 hour before a meal reduces bioavailability by 30%[FDA Label].
HALF-LIFE
The initial half life of risedronic acid is approximately 1.5 hours[T536], with a terminal half life of 561 hours[FDA Label].
DESCRIPTION
Risedronate is a bisphosphonate drug.
(GtoPdb)
DESCRIPTION
Selective sirtuin family deacetylase inhibitor
(Tocris Bioactive Compound Library)
DESCRIPTION
Risedronate Sodium is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis, and treat Paget's disease of bone.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
5
Organisms
9
Compound Sets
32
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine BioReference Compounds
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
NCATS Inxight Approved Drugs
NPC Screening Collection
Other bioactive compounds
Prestwick Chemical Library
Probe Miner (suitable probes)
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
Tocris Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
76
Molecular Weight
283.0
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
5
Rotatable Bonds
4
Ring Count
1
Aromatic Ring Count
1
cLogP
-0.37
TPSA
148.18
Fraction CSP3
0.29
Chiral centers
0.0
Largest ring
6.0
QED
0.47
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Microbiology&virology
Anti-infection
Target
HAP
FPS
FDPS
Parasite
Primary Target
Other Synthases/Synthetases
MOA
HBV inhibitor
Others inhibitor
Others antagonist
Transferase antagonist
Inhibitor
osteoclast inhibitor
Indication
osteoporosis, Paget's disease
Disease Area
orthopedics, endocrinology
Therapeutic Class
Bone Density Conservation Agents
Source data
